Bimagrumab – Forschung

Blocking the activin IIB receptor with bimagrumab (BYM338) increases walking performance: A meta-analysis.

Spitz RW, Dankel SJ, Bell ZW, Wong V, Abe T, Kang M · Geriatr Gerontol Int (2021)

Efficacy and safety of pharmacological treatments in inclusion body myositis: a systematic review.

Santos EJF, Farisogullari B, Yapp N, Townsley H, Sousa P, Machado PM · RMD Open (2025)

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial

Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM, BELIEVE trial investigators. · Nature medicine (2026)

Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial.

Rooks D, Swan T, Goswami B, Filosa LA, Bunte O, Panchaud N · JAMA Netw Open (2020)

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.

Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O · Neurology (2021)

Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes.

Garito T, Zakaria M, Papanicolaou DA, Li Y, Pinot P, Petricoul O · Clin Endocrinol (Oxf) (2018)

Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial.

Hofbauer LC, Witvrouw R, Varga Z, Shiota N, Cremer M, Tanko LB · Lancet Healthy Longev (2021)

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.

Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H · Lancet Neurol (2019)

Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy.

Rooks DS, Laurent D, Praestgaard J, Rasmussen S, Bartlett M, Tankó LB · J Cachexia Sarcopenia Muscle (2017)

Treatment of sporadic inclusion body myositis with bimagrumab.

Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J · Neurology (2014)

Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial.

Polkey MI, Praestgaard J, Berwick A, Franssen FME, Singh D, Steiner MC · Am J Respir Crit Care Med (2019)

Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338).

Petricoul O, Nazarian A, Schuehly U, Schramm U, David OJ, Laurent D · Clin Pharmacokinet (2023)

Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults.

Rooks D, Yates DP, Neelakantham S, Praestgaard J, Cury RC, Lamb HJ · J Clin Endocrinol Metab (2026)

Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial.

Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O · JAMA Netw Open (2021)

Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.

Garito T, Roubenoff R, Hompesch M, Morrow L, Gomez K, Rooks D · Diabetes Obes Metab (2018)

Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study.

Rooks D, Praestgaard J, Hariry S, Laurent D, Petricoul O, Perry RG · J Am Geriatr Soc (2017)

Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort.

Rooks D, Petricoul O, Praestgaard J, Bartlett M, Laurent D, Roubenoff R · J Cachexia Sarcopenia Muscle (2020)

New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?

Einfach gesagt: This narrative review discusses the justification for focus on lean mass preservation and reviews the status of relevant drugs in development.

Ryan DH. · Reviews in endocrine & metabolic disorders (2025)

Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes

Einfach gesagt: Preliminary findings are promising, but larger, controlled trials are necessary to confirm efficacy and safety before clinical implementation can be considered.

Aimelet V, Holst JJ. · Diabetes, obesity & metabolism (2026)

The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation

Einfach gesagt: For the time being, considerations like advanced age and prefrailty may affect the choice of suitable candidates in clinical practice for current and emerging anti-obesity medications due to the associated risk of sarcopenia.

Stefanakis K, Kokkorakis M, Mantzoros CS. · Metabolism: clinical and experimental (2024)